

PUBLISHING IN NEUROLOGICAL JOURNALS: FACTS, MYTHS AND FUTURE

Jacqueline A French MD

Department of Neurology

NYU Grossman School of Medicine

Disclosures

- **J. French receives salary support from the Epilepsy Foundation and from Epilepsy Study Consortium for consulting work and/or attending Scientific Advisory Boards for** Acadia Pharmaceuticals, Access Industries, Acuta Capital Partners, AFASCI Inc, Agrithera, Inc., Alterity Therapeutics Limited, Angelini Pharma S.p.A, Autifony Therapeutics Limited, Axonis Therapeutics, Bain Capital, Beacon Biosignals, Inc., Biogen, Biohaven Pharmaceuticals, Bloom Science Inc., Bright Minds Biosciences, Inc., Capsida Biotherapeutics, Cerebral Therapeutics, Cerecin Inc., Cerevel, Ceribell, Cognizance Biomarkers, Cowen and Company, LLC, Crossject, EcoR1 Capital, EG 427, Eisai, Encoded Therapeutics, Engrail, EpiMinder, Epitel Inc, Grin Therapeutics, Harmony/Epygenix, Ionis Pharmaceuticals, iQure Pharma Inc, IQVIA RDS Inc, Janssen Pharmaceutica, Jazz Pharmaceuticals, Leal Therapeutics Inc, LivaNova, London Research & Pharmaceuticals, Longboard Pharmaceuticals, Maplight Therapeutics, Marinus, Medscape/Web MD, Modulight.bio, Mosaica Therapeutics, Neumirna Therapeutics, Neurelis, Neurocrine, Neurona Therapeutics, NeuroPace, Inc., NeuroPro Therapeutics, Neuroventis, Neurvati, Noema Pharma, Ono Pharmaceutical Co., Otsuka Pharmaceutical Development, Ovid Therapeutics Inc., Praxis, PureTech LTY Inc., Rapport Therapeutics, Inc., Receptor Holdings Inc., Rivervest Venture Partners, Sage Therapeutics, Inc., SK Life Sciences, Stoke, Stream Neuroscience, Supernus, Takeda, Taysha Gene Therapies, UCB Inc., uniQure, Ventus Therapeutics, Vida Ventures Management, Xenon.
- J. French has also received research support from the Epilepsy Study Consortium (Funded by Eisai and UCB,) Epilepsy Study Consortium/Epilepsy Foundation (Funded by UCB), GW/FACES/One8Foundation, NINDS and Praxis.
- She is on the editorial board of Lancet Neurology and Neurology Today. She is Medical Director for the Epilepsy Foundation. She is the President and on the Board of Directors for the Epilepsy Study Consortium, Inc.
- She has received travel/meal reimbursement related to research, advisory meetings, or presentation of results at scientific meetings from the Epilepsy Study Consortium, the Epilepsy Foundation, Biohaven Pharmaceuticals, Cerebral Therapeutics, Ceribell, Cowen and Company, LLC, Harmony Biosciences, LivaNova, Longboard, Maplight Therapeutics, Neumirna Therapeutics, Neurocrine, NeuroPace Inc., Neurvati, Praxis, Rapport, SK Life Science, Supernus, Takeda, Ventus, Xenon.

Learning objective(s)


- Understand the types of journals available for publishing
- Recognize which journals are a good fit for your paper
- Explain how an impact factor is generated, and what it means
- Discuss how a journal processes an article
- Understand what steps can be taken when an article is rejected

Key Messages: Understanding the Landscape

- Journal scope matters—It is important to tailor your submission to an appropriate journal
 - Too broad-They may not accept, which leads to substantial waste of time
 - But aim as high as appropriate. Impact factor matters in terms of getting your work in front of as many eyes as possible

Key Messages: Things many people don't know

- Yes, sometimes the reviewer knows less than you!
 - It is getting increasingly hard to find reviewers
 - But if the reviewer doesn't get the point of your work likely others will be in the same boat
- The largest rejection rate comes at the beginning
 - For higher impact journals, such as Neurology and Annals of Neurology, Rejection rate may be 80%, but 50-60% of articles are rejected without review in a few days to a week. Of the remaining 40-50%, 1/3 to 50% will be accepted.
- A rejection may not be “final”
 - If you truly believe a reviewer did not understand your work, you can (or your mentor can on your behalf) appeal for a second chance (it sometimes works!)
- If you are rejected, don't always lower your expectations-It is possible to re-tool and get the paper accepted at another journal with a higher or similar impact factor



Data from Publisher's report, Annals of Neurology 2025

Key Messages: What happens if you are rejected

- Recently, many journals will refer you to a “sister” journal, with encouraging wording
- The journal you are referred to may have associated fees, and may have a very different impact factor-
 - It may be the right choice, but it may not
 - Either way, if the article was reviewed, read the reviews carefully